HGF and gastric cancer: The c-MET inhibitor, such as Su11274, monotherapy or combined with irinotecan have achieved positive outcomes, other c-MET inhibitor, such as KRC-408, KRC-00715, Simm 530 and multitargeted kinase inhibitor T-1840383 effectively suppressed the proliferation of gastric cancer cells and growth of tumor xenograft 15, besides, a multinational phase 2 study shown the monoclonal antibody which binds the MET-ligand HGF (Rilotumumab) combined with epirubicin, cisplatin, and capecitabine (ECX) could make benefit for MET-positive advanced oesophagogastric cancer patients 29.